Tirzepatide

Mechanism

Tirzepatide is a dual-action peptide that activates both GLP-1 and GIP receptors — two key gut hormones involved in blood sugar regulation and appetite control. By targeting two pathways simultaneously, it produces even greater weight loss and blood sugar improvements than GLP-1-only drugs like semaglutide. Clinical trials have shown average weight loss of 20-25% of body weight, making it one of the most effective metabolic peptides ever developed.

Effects

## Metabolic System [Tier 1 - Extensive Phase III Human Data] - Dual GIP and GLP-1 receptor agonist — first-in-class twincretin - GIP receptor agonism potentiates insulin secretion, improves adipose tissue lipid handling, and may enhance GLP-1 receptor sensitivity through receptor crosstalk - SURMOUNT-1: 22.5% mean body weight loss at 15mg over 72 weeks (highest of any approved anti-obesity medication) - SURPASS trials: HbA1c reductions of 2.0-2.3% in type 2 diabetes, superior to semaglutide 1mg - Fasting insulin levels decrease substantially, reflecting improved insulin sensitivity beyond weight loss alone ## Gastrointestinal System [Tier 1 - Well-Characterized] - Delays gastric emptying by 30-60 minutes (GLP-1 effect), contributing to satiety and post-prandial glucose control - Nausea (12-24%), diarrhea (12-17%), and constipation (6-10%) are most common, dose-dependent, and typically resolve within 4-8 weeks - Rare cases of gastroparesis-like symptoms at higher doses — more common in patients with pre-existing diabetic autonomic neuropathy - GI side effects are modestly lower than semaglutide at equivalent weight-loss efficacy in head-to-head (SURMOUNT-5 data) ## Cardiovascular System [Tier 1 - Human Data] - SURMOUNT-MMO cardiovascular outcomes trial showed 10% reduction in MACE (initial readout) - Systolic blood pressure reductions of 6-9 mmHg at therapeutic doses - Triglyceride reductions of 20-25%, LDL reductions of 5-10%, HDL increases of 3-5% - C-reactive protein (hs-CRP) reductions of 30-40%, indicating systemic anti-inflammatory effects - Heart failure with preserved ejection fraction (HFpEF): SUMMIT trial showed significant improvement in heart failure composite score ## Hepatic System [Tier 1 - Human Data] - Liver fat reductions of 50-65% measured by MRI-PDFF in SYNERGY-NASH trial - ALT normalization in majority of patients with elevated baseline values - Histological improvement in MASH confirmed in biopsy substudies - Mechanism: improved insulin sensitivity reduces de novo lipogenesis; weight loss reduces hepatic lipid delivery ## Endocrine/Pancreatic System [Tier 1 - Human Data] - Restores first-phase insulin secretion in type 2 diabetes (lost early in disease progression) - Improves beta-cell function indices (HOMA-B, disposition index) dose-dependently - GIP receptor activation on alpha cells may modulate glucagon in a glucose-dependent manner - No clinically significant effects on thyroid function tests, though GLP-1 class carries MTC boxed warning from preclinical rodent data ## Musculoskeletal System [Tier 2 - DXA Substudy Data] - Lean mass loss is proportional to total weight loss (~25-35% of weight lost is lean mass) — similar ratio to other GLP-1 class drugs - GIP receptor activation in bone may theoretically support bone mineral density, but clinical data are limited - Resistance training during tirzepatide therapy significantly attenuates lean mass loss (TOPSET trial data) ## Central Nervous System [Tier 2 - Secondary Endpoints/Observational] - Significant improvements in patient-reported quality of life, physical functioning, and eating behavior scores - Reductions in food craving and hunger hormones (ghrelin suppression) - Emerging observational data suggest reduced alcohol and substance use desire (GLP-1 class effect on mesolimbic reward circuitry) - No cognitive impairment signals; some patients report improved mental clarity (likely secondary to metabolic improvement) ## Renal System [Tier 2 - Secondary Endpoints] - Reductions in UACR (urinary albumin-to-creatinine ratio) in diabetic nephropathy - eGFR stabilization in patients with early CKD - Mechanism likely multifactorial: weight loss, BP reduction, glucose improvement, direct tubular effects

Practitioner Guide

## Clinical Positioning Tirzepatide is the most effective FDA-approved weight loss medication as of early 2026. It is the standard against which all other metabolic peptides are compared. The dual GIP/GLP-1 mechanism provides superior weight loss to semaglutide with a comparable or slightly better GI tolerability profile. ## Prescribing Basics - Available as: Mounjaro (T2DM), Zepbound (obesity/overweight), and compounded tirzepatide - Brand: single-dose auto-injector pens, weekly SC injection - Compounded: typically multi-dose vial, reconstituted with bacteriostatic water ## Dosing Protocol Starting: 2.5mg SC weekly x 4 weeks (this is a titration dose, not therapeutic) Escalation: 5mg → 7.5mg → 10mg → 12.5mg → 15mg (each step held 4 weeks minimum) Maintenance: most patients achieve goals at 10-15mg; some respond well at 7.5mg Maximum: 15mg weekly (studied doses) ## Practical Dosing Tips - ALWAYS start at 2.5mg regardless of body weight — no loading dose - If nausea is significant at any dose, hold at that dose for 8 weeks instead of 4 before escalating - Injection site: abdomen, thigh, upper arm — rotate sites - Timing: same day each week, any time of day, with or without food - If a dose is missed: take within 4 days of missed dose; if >4 days, skip and resume on next scheduled day - Compounded tirzepatide: verify source purity, ensure proper reconstitution (typically 2-5mg/mL concentrations) ## What to Expect (Timeline) - Weeks 1-4 (2.5mg): minimal weight loss, possible mild nausea, appetite reduction begins - Weeks 5-12 (5-7.5mg): appetite suppression becomes pronounced, 3-5% weight loss, energy may fluctuate - Weeks 12-24 (7.5-10mg): steady weight loss of 1-2 lbs/week, improved bloodwork, sleep quality often improves - Weeks 24-52 (10-15mg): approaching maximal effect, 15-20% total weight loss in most responders - Weeks 52-72: continued slow weight loss or weight stabilization at new set point ## Blood Work Protocol Baseline: CBC, CMP, lipid panel, HbA1c, fasting insulin, thyroid panel, liver enzymes, amylase/lipase Month 3: CMP, lipid panel, HbA1c, liver enzymes, amylase/lipase Month 6: comprehensive panel repeat Ongoing: every 3-6 months based on clinical response ## Side Effect Management - Nausea: eat small frequent meals, avoid high-fat meals, ginger tea/capsules, ondansetron 4mg PRN - Constipation: fiber supplementation, adequate hydration (many patients undereat AND underdrink), magnesium citrate - Sulfur burping (eructation): reduce high-fat/high-sulfur foods, simethicone, slower eating - Hair thinning: typically at 3-6 months due to rapid weight loss (telogen effluvium), not drug-specific — biotin, protein optimization, usually self-resolving - Injection site reactions: rare, rotate sites, ensure room-temperature injection ## Contraindications & Cautions - Absolute: personal/family history of medullary thyroid carcinoma or MEN2, prior serious hypersensitivity - Relative: history of pancreatitis (monitor closely), severe gastroparesis, pregnancy/breastfeeding - Drug interactions: may affect absorption of oral medications due to delayed gastric emptying (oral contraceptives, levothyroxine — take 1 hour before tirzepatide injection day) - Gallstones: increased risk with rapid weight loss — counsel patients, low threshold for RUQ ultrasound if symptomatic ## Stacking Considerations - With metformin: complementary mechanisms, often continued together for T2DM - With testosterone (in hypogonadal males): weight loss improves endogenous T; monitor and adjust TRT - With GH peptides (ipamorelin/CJC-1295): theoretical benefit for lean mass preservation during weight loss, but no clinical trial data for combination - NOT with other GLP-1 agonists (semaglutide, liraglutide): redundant mechanism, increased GI side effects, no benefit - With resistance training: strongly recommended to preserve lean mass — the single most important adjunct ## Compounded vs. Brand Considerations - Brand (Mounjaro/Zepbound): standardized dosing, FDA-regulated manufacturing, auto-injector convenience, insurance coverage variable - Compounded: typically lower cost, requires manual injection (insulin syringe), quality varies by pharmacy, available during shortage periods under FDA enforcement discretion - Key quality markers for compounded: sterility testing (USP 797 compliance), endotoxin testing, potency verification, proper cold-chain shipping

Dosing Protocols

Contraindications & Cautions

• hard stop — History of pancreatitis
  GLP-1/GIP receptor agonists are associated with increased risk of pancreatitis. Patients with a history of pancreatitis are at substantially elevated risk of recurrence.
  Action: Do not use. This is a contraindication per prescribing information. Refer to physician for alternative therapies.
• hard stop — Medullary thyroid carcinoma or MEN2 syndrome
  GIP/GLP-1 receptor agonists carry thyroid C-cell tumor risk based on rodent studies. Patients with personal or family history of MTC or MEN2 are at unacceptable risk.
  Action: Absolutely contraindicated. Do not use under any circumstances. This is a black box warning. Refer to oncologist/endocrinologist.
• hard stop — Pregnancy
  GIP/GLP-1 agonists have demonstrated adverse developmental effects in animal studies. Weight loss during pregnancy may cause fetal harm.
  Action: Discontinue immediately if pregnancy is detected. Do not initiate during pregnancy. Advise contraception during use.
• hard stop — Breastfeeding
  Insufficient data on excretion in human breast milk. Potential risk to nursing infant. Risk-benefit does not support use.
  Action: Do not use while breastfeeding.
• hard stop — Gastroparesis
  Dual GIP/GLP-1 agonism significantly delays gastric emptying. Pre-existing gastroparesis creates risk of severe GI complications including gastric retention and aspiration.
  Action: Do not use in patients with diagnosed gastroparesis. Refer to gastroenterologist.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use. Developing endocrine, metabolic, and neurological systems may be adversely affected. Insufficient safety data in minors.
  Action: Do not provide peptide protocols to individuals under 18. Refer to pediatric endocrinologist if clinically appropriate.
• hard stop — Other GLP-1 receptor agonists
  Concurrent use of multiple GLP-1 receptor agonists causes dangerous additive effects on gastric emptying, appetite suppression, and insulin secretion.
  Action: Never combine multiple GLP-1 agonists. Ensure adequate washout before switching.
• requires physician — Insulin
  Concurrent use with insulin significantly increases risk of hypoglycemia. Dual GIP/GLP-1 agonism further potentiates insulin-mediated glucose uptake.
  Action: Do not initiate without physician supervision. Insulin dose reduction typically required. Frequent blood glucose monitoring mandatory.
• requires physician — Sulfonylureas
  Sulfonylureas stimulate insulin secretion independent of blood glucose. Combined with dual GIP/GLP-1 agonism, severe hypoglycemia risk increases substantially.
  Action: Physician must evaluate sulfonylurea dose reduction before initiating. Blood glucose monitoring required. Educate on hypoglycemia signs and management.
• monitor — Metformin
  Dual GIP/GLP-1 agonism slows gastric emptying, which may alter metformin absorption kinetics. Additive gastrointestinal side effects are common.
  Action: Monitor for increased GI side effects. No dose adjustment typically required. Ensure adequate hydration. Monitor blood glucose during titration.
• requires physician — History of eating disorders
  Dual GIP/GLP-1 agonism causes significant appetite suppression and weight loss which may trigger eating disorder relapse or exacerbate disordered eating behaviors.
  Action: Requires physician evaluation and mental health screening before initiation. Ongoing monitoring recommended.

Evidence

• Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials

  Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ (2025) — Ann Intern Med — PMID: 39761578

  Retatrutide 12mg/week produced greatest weight loss: 22.1% at 48 weeks. Tirzepatide 15mg/week: 17.8% at 72 weeks. Semaglutide 2.4mg/week: 13.9% at 68 weeks. Liraglutide 3.0mg/day: 5.8% at 26 weeks. AEs predominantly gastrointestinal (nausea, vomiting, diarrhea), mostly mild-moderate. Serious AEs rare (0-10%). Retatrutide is most efficacious agent yet tested for obesity without diabetes.

  strong

• Tirzepatide for overweight and obesity management

  Hamza M, Papamargaritis D, Davies MJ (2025) — Expert Opin Pharmacother — PMID: 39632534

  Tirzepatide (GLP-1/GIP dual agonist) enables ≥20% weight loss in many patients. SURMOUNT program confirms efficacy across metabolic, cardiac and liver complications. SURMOUNT-OSA: significant improvement in sleep apnea. SYNERGY-NASH: improvements in MASH/fatty liver. SUMMIT: benefits in heart failure with preserved ejection fraction. Approved at 5/10/15mg for T2D and obesity. Safety profile similar to GLP-1 RAs.

  strong

• Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

  Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A (2022) — New England Journal of Medicine — PMID: 35658024

  Tirzepatide produced dose-dependent mean weight reductions of -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) vs -3.1% with placebo over 72 weeks. At the highest dose, 36.2% of participants achieved >= 25% weight loss. Most common adverse events were GI (nausea, diarrhea, constipation), generally mild-to-moderate.

  strong

• Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-5)

  Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodriguez A (2022) — JAMA Internal Medicine

  Tirzepatide as add-on to insulin glargine showed superior HbA1c reductions and significant weight loss vs placebo add-on in patients with T2D on basal insulin. Demonstrated efficacy even in insulin-treated populations with long-standing diabetes.

  strong

• Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)

  Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, Liu B, Cui X, Brown K (2021) — New England Journal of Medicine — PMID: 34170647

  Tirzepatide at all doses (5, 10, 15 mg) was superior to semaglutide 1 mg for HbA1c reduction (mean -2.01% to -2.30% vs -1.86%) and weight loss (-7.6 to -11.2 kg vs -5.7 kg) over 40 weeks in T2D patients. More patients achieved HbA1c < 7% and < 5.7% with tirzepatide.

  strong

Stacks featuring this peptide

Research Summary

## Tier 1 — Landmark Human Clinical Trials - SURPASS program (T2DM): SURPASS 1-5 trials, >5000 patients total. HbA1c reductions of 1.9-2.3% and weight loss of 7-13 kg across doses. SURPASS-2 head-to-head vs. semaglutide 1mg: tirzepatide superior on both HbA1c and weight loss. - SURMOUNT program (obesity): SURMOUNT 1-4 trials. SURMOUNT-1: 22.5% weight loss at 15mg (72 weeks), with 63% achieving ≥20% weight loss. SURMOUNT-2 (T2DM + obesity): 14.7% weight loss at 15mg. - SURMOUNT-5: head-to-head vs. semaglutide 2.4mg — tirzepatide 15mg achieved ~5% greater weight loss (preliminary data) - SURMOUNT-MMO: cardiovascular outcomes — initial MACE reduction readout positive - SUMMIT (HFpEF): significant improvement in Kansas City Cardiomyopathy Questionnaire score, exercise tolerance, NT-proBNP reduction, and composite heart failure events - SYNERGY-NASH: liver histology improvement in MASH patients ## Tier 2 — Mechanistic and Substudy Data - GIP receptor activation on adipocytes promotes lipid storage and adiponectin release, potentially explaining improved insulin sensitivity beyond weight loss - Receptor crosstalk: GIP agonism may sensitize GLP-1 receptors through CREB-mediated GLP-1R upregulation - Clamp studies show improved peripheral and hepatic insulin sensitivity disproportionate to weight loss - DXA composition data: ~30% of weight lost is lean mass, improved with exercise intervention - Brain PET/fMRI studies show reduced food reward signaling in hypothalamus and nucleus accumbens ## Tier 3 — Preclinical - Original molecule design based on GIP backbone with GLP-1 agonist residues, fatty acid linker for half-life extension - Mouse models show superior weight loss and metabolic improvement vs. selective GLP-1 or GIP agonists alone - GIP receptor agonism paradox: GIP was historically considered obesogenic, but chronic agonism (vs. acute) appears to desensitize adipose GIP signaling while retaining pancreatic benefits ## Evidence Gaps - Long-term (>3 year) efficacy and safety data still accumulating - Weight regain after discontinuation appears similar to GLP-1 agonists (~2/3 of weight regained within 1 year of stopping) - Optimal maintenance dosing strategy (dose reduction vs. full dose indefinitely) not established - Cancer risk: theoretical concern from GLP-1R/GIPR activation on various tissues — long-term post-marketing surveillance ongoing - Pediatric data limited (trials underway)